US Patent 7230083 Anti-alphabeta3 humanized monoclonal antibodies
Patent 7230083 was granted and assigned to Smithkline Beecham Limited on June, 2007 by the United States Patent and Trademark Office.
All edits
Edits on 16 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Alexander Taylor0
Kyung O Johanson0
Zdenka L Jonak0
Edits on 1 Sep, 2023
Golden AI
Edits made to:
Article (+337 characters)
Article
Patent abstract
This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin αvβ3 receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of αvβ3-mediated disorders, such as restenosis, in human patients.
Edits on 22 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 13 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07230083 Anti-alphabeta3 humanized monoclonal antibodies US Patent 7230083 Anti-alphabeta3 humanized monoclonal antibodies
Infobox
Patent Number
072300830
Patent Number
72300830
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
072300830
Date of Patent
June 12, 2007
0Patent Application Number
102238800
Date Filed
August 20, 2002
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 21 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07230083 Anti-alphabeta3 humanized monoclonal antibodies
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07230083
Date of patent
June 12, 2007
Patent application number
10223880
Date Filed
August 20, 2002
Patent primary examiner
Find more entities like US Patent 7230083 Anti-alphabeta3 humanized monoclonal antibodies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
